Statins for primary prevention of cardiovascular disease
Abstract
Paula Byrne, John Cullinan, and Susan Smith explain the uncertainties about the benefits of statins, particularly in people at low risk of cardiovascular disease, and the need for better data to help shared decision making
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described.
“The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described.”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [5]
Recent data are limited on the effects of statins or other adjunctive treatments in patients without a history of a cardiovascular event.
“Recent data are limited on the effects of statins or other adjunctive treatments in patients without a history of a cardiovascular event, leading some authors to question whether the benefits of cholesterol lowering exceed the harms in these patients.[4][5][6][7]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [5]
Primary prevention patients are currently undertreated with lipid-modulating therapies.
“Primary prevention patients are currently undertreated with lipid-modulating therapies.[4][5][6][7]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [5]
Cites
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457 · see citing works
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251 · see citing works
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · see citing works
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · see citing works
Saini, P., Loke, Y. K., Gamble, C., Altman, D. G., Williamson, P. R., & Kirkham, J. J. (2014) · BMJ · doi:10.1136/bmj.g6501 · Cited by 209 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen, S. E., Menon, V., Nicholls, S. J., Brennan, D., Laffin, L., Ridker, P., Ray, K. K., Mason, D., Kastelein, J. J. P., Cho, L., et al. (2023) · JAMA · doi:10.1001/jama.2023.9696 · Cited by 146 · see citing works
- Authors
- Byrne, P., Cullinan, J., & Smith, S. M.
- Affiliations
- Ollscoil na Gaillimhe – University of Galway (IE)
- Royal College of Surgeons in Ireland (IE)
- Corresponding author
- Byrne, Paula
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-10-16
- Volume
- 367
- Pages
- l5674
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W3148824586
- Cited by
- 53
- References
- 6
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 7 · 2020: 16 · 2019: 3
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Health Research Board (SPHeRE/2013/1)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- statins, primary prevention, cardiovascular disease, low cardiovascular risk, shared decision-making, cardiovascular risk assessment
- MeSH terms
- Attitude of Health Personnel, Cardiovascular Diseases, Decision Making, Eligibility Determination, Humans, Primary Prevention, Practice Guidelines as Topic, Risk Assessment, Patient Selection, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Patient Preference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
